Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
0.080 Biomarker disease BEFREE TBX1 Functions as a Tumor Suppressor in Thyroid Cancer Through Inhibiting the Activities of the PI3K/AKT and MAPK/ERK Pathways. 30543152 2019
Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
0.080 Biomarker disease BEFREE <b>Conclusions</b>: Our data demonstrate that vitamin C kills thyroid cancer cells by inhibiting MAPK/ERK and PI3K/AKT pathways via a ROS-dependent mechanism and suggest that pharmaceutical concentration of vitamin C has potential clinical use in thyroid cancer therapy. 31285773 2019
Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
0.080 Biomarker disease BEFREE Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancer. 30978703 2019
Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
0.080 Biomarker disease BEFREE DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers. 28910386 2017
Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
0.080 Biomarker disease BEFREE Our study illustrates a new pathway comprising iodine, miRNA and MAPK1, and defines a novel mechanism in thyroid cancer. 28992617 2017
Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
0.080 AlteredExpression disease BEFREE The aim of this study is to identify its expression, function, and molecular mechanism in thyroid cancer. microRNA-137 (miR-137) downregulation was observed in thyroid cancer tissues compared with normal thyroid tissues. miR-137 mimics downregulated B-CPAP cell proliferation, colony formation ability, and invasion, with suppressed expression of cyclin E, MMP2, p-ERK, and p-AKT. miR-137 inhibitor transfection in TPC-1 cell line showed the opposite effects. 26695142 2016
Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
0.080 Biomarker disease BEFREE These results suggest that the AMPK and p38 MAPK signaling pathways may be useful therapeutic targets to treat thyroid cancer. 25045295 2014
Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
0.080 AlteredExpression disease BEFREE Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway. 23559083 2013